Oral sessions summaries


Ankylosing Spondylitis

Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study

Atul Deodhar, MD

Expert commentary by Sofia Ramiro, MD, Msc, PhD

ACR Convergence 2020 - Oral session summaries - Abs #L11

View
Ankylosing Spondylitis

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis: 1-year results from a randomized, double-blind, placebo-controlled study with open-label extension

Atul Deodhar, MD

Expert commentary by Sofia Ramiro, MD, Msc, PhD

ACR Convergence 2020 - Oral session summaries - Abs #2023

View
Axial Spondyloarthritis

Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial

Xenofon Baraliakos, MD, PhD

Expert commentary by Fabian Proft, MD

ACR Convergence 2020 - Oral session summaries - Abs #0505

View
Axial Spondyloarthritis

Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A multicenter study with 806 patients

Inigo Gonzalez-Mazon, MD

Expert commentary by Elena Myasoedova, MD, PhD

ACR Convergence 2020 - Oral session summaries - Abs #0448

View
Axial Spondyloarthritis

Predictors of maintaining inactive disease after etanercept withdrawal, and regaining inactive disease status after flare and retreatment, in adults with non-radiographic axial spondyloarthritis: results from RE-EMBARK

Filip Van den Bosch, MD, PhD

Expert commentary by Marina N. Magey, MD

ACR Convergence 2020 - Oral session summaries - Abs #2028

View
Behçet Syndrome

Efficacy of apremilast for the treatment of manifestations of Behçet’s syndrome other than oral ulcers, including skin lesions and arthritis

Gülen Hatemi, MD

Expert commentary by Abhijeet Danve, MD, FACP

ACR Convergence 2020 - Oral session summaries - Abs #0512

View
Giant Cell Arteritis

Characteristics of giant cell arteritis flares after successful treatment with tocilizumab: results from the long-term extension of a randomized controlled phase 3 trial

Sebastian Unizony, MD

Expert commentary by Christian Dejaco, MD, PhD, MBA

ACR Convergence 2020 - Oral session summaries - Abs #0516

View
Lupus Nephritis

Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis

Richard Furie, MD

Expert commentary by Laura Andreoli, MD, PhD

ACR Convergence 2020 - Oral session summaries - Abs #0988

View
Psoriatic Arthritis

Efficacy and safety of guselkumab, a monoclonal antibody specific to the p19-subunit of interleukin-23, through week 52 of a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis

Iain McInnes, MD, PhD

Expert commentary by Siba P Raychaudhuri, MD

ACR Convergence 2020 - Oral session summaries - Abs #0506

View
Psoriatic Arthritis

Efficacy and safety of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis in a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study

Philip Mease, MD

Expert commentary by Siba P Raychaudhuri, MD

ACR Convergence 2020 - Oral session summaries - Abs #2027

View
Psoriatic Arthritis

Integration of clinical and protein markers through machine learning to distinguish patients with psoriasis arthritis from those with psoriasis without psoriatic arthritis

Sara Rahmati, MD

Expert commentary by Siba P Raychaudhuri, MD

ACR Convergence 2020 - Oral session summaries - Abs #0502

View
Psoriatic Arthritis

Multimorbidity in rheumatoid arthritis, psoriatic arthritis, gout, and osteoarthritis within the Rheumatology Informatics System for Effectiveness (RISE) registry

Bryant England, MD, PhD

Expert commentary by Marina N. Magey, MD

ACR Convergence 2020 - Oral session summaries - Abs #2021

View
Psoriatic Arthritis

The reliability of scoring sonographic entheseal abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) study

Lihi Eder, MD, PhD

Expert commentary by Abhijeet Danve, MD, FACP

ACR Convergence 2020 - Oral session summaries - Abs #2021

View
Rheumatoid Arthritis

Prevalence, incidence, and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older patients with rheumatoid arthritis: a nationwide cohort study

Jeffrey Sparks, MD

Expert commentary by Richard Conway, MB BCh BAO, PhD

ACR Convergence 2020 - Oral session summaries - Abs #0489

View
Rheumatoid Arthritis

A phase 2b, randomized, double-blind study in patients with rheumatoid arthritis evaluating the safety and efficacy of evobrutinib compared with placebo in patients with an inadequate response to methotrexate

Maya Buch, MD, PhD

Expert commentary by Jonathan Kay, MD

ACR Convergence 2020 - Oral session summaries - Abs #2012

View
Rheumatoid Arthritis

Non-obese rheumatoid arthritis patients with low low-density lipoprotein have higher coronary atherosclerosis burden, greater plaque progression and cardiovascular event risk

George Karpouzas, MD

Expert commentary by Elena Myasoedova, MD, PhD

ACR Convergence 2020 - Oral session summaries - Abs #0485

View
Rheumatoid Arthritis

Stable versus tapered and withdrawn treatment with tumor necrosis factor inhibitor in rheumatoid arthritis remission: a randomized, open-label, phase 4, non-inferiority trial

Siri Lillegraven, MD, PhD

Exert commentary by Kevin Winthrop, MD

ACR Convergence 2020 - Oral session summaries - Abs #2010

View
Rheumatoid Arthritis

Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib

Kevin Winthrop, MD, MPH

Expert commentary by Abhijeet Danve, MD, FACP

ACR Convergence 2020 - Oral session summaries - Abs #1002

View
Rheumatoid Arthritis

Can a Clinical Disease Activity Index based on patient-reported joint counts (PT-CDAI) be used to inform target-based care in telemedicine? An analysis of 2 early RA cohort studies

Vivian Bykerk, MD

Expert commentary by Marina N. Magey, MD

ACR Convergence 2020 - Oral session summaries - Abs #0483

View